| 1.21 -0.02 (-1.63%) | 01-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.44 | 1-year : | 1.48 |
| Resists | First : | 1.23 | Second : | 1.26 |
| Pivot price | 1.21 | |||
| Supports | First : | 1.18 | Second : | 0.98 |
| MAs | MA(5) : | 1.22 |
MA(20) : | 1.2 |
| MA(100) : | 1.06  |
MA(250) : | 3.45 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 37.1 |
D(3) : | 55.3 |
| RSI | RSI(14): 53.8 | |||
| 52-week | High : | 11.31 | Low : | 0.81 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ RAIN ] has closed above bottom band by 47.5%. Bollinger Bands are 62.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.21 - 1.22 | 1.22 - 1.22 |
| Low: | 1.19 - 1.2 | 1.2 - 1.21 |
| Close: | 1.2 - 1.21 | 1.21 - 1.22 |
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
Sat, 27 Jan 2024
Rain Therapeutics Merges with Pathos AI Subsidiary - TipRanks.com - TipRanks
Fri, 26 Jan 2024
Pathos AI Completes Acquisition of Rain Oncology - Business Wire
Sat, 20 Jan 2024
Rain Therapeutics Enters Merger with Pathos AI Despite Legal Hurdles - TipRanks.com - TipRanks
Thu, 14 Dec 2023
Rain ends stormy year by opting to be acquired by Pathos AI - Fierce Biotech
Wed, 13 Dec 2023
Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value ... - GlobeNewswire
Mon, 16 Oct 2023
Concentra offers to buy troubled Rain Oncology - Fierce Biotech
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 28 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 16.4 (%) |
| Held by Institutions | 68.3 (%) |
| Shares Short | 661 (K) |
| Shares Short P.Month | 537 (K) |
| EPS | -2.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.86 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -52.2 % |
| Return on Equity (ttm) | -97.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.67 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -66 (M) |
| Levered Free Cash Flow | -43 (M) |
| PE Ratio | -0.59 |
| PEG Ratio | 0 |
| Price to Book value | 0.65 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|